Long-term trajectories of hepatic and metabolic biomarkers after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral therapy-experienced people with HIV with and without hepatic coinfection: Data from the ICONA cohort

•Hepatic injury markers declined over 2 years after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV.•Reduction was stronger in patients with hepatitis B surface antigen+ and those with baseline chronic enzyme elevation.•Lipid parameters increased mainly in th...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of infectious diseases Vol. 161; p. 108081
Main Authors:	Poliseno, Mariacristina, Caputo, Sergio Lo, Tavelli, Alessandro, Gagliardini, Roberta, Gazzola, Lidia, Saracino, Annalisa, Santantonio, Teresa Antonia, Squillace, Nicola, Puoti, Massimo, Mazzotta, Valentina, Antinori, Adndrea, d’Arminio Monforte, Antonella, Cozzi-Lepri, Alessandro
Format:	Journal Article
Language:	English
Published:	Canada Elsevier Ltd 01.12.2025 Elsevier
Subjects:	Adenine - analogs & derivatives Adenine - therapeutic use Adult Alanine Alanine Transaminase - blood ALT Anti-HIV Agents - therapeutic use Biomarkers - blood Cholesterol Cohort Studies Coinfection - drug therapy Drug Substitution Female Hepatitis B - complications Hepatitis B - drug therapy HIV Infections - complications HIV Infections - drug therapy HIV Infections - metabolism HIV/HBV coinfection Humans Infectious Disease Liver - drug effects Liver - metabolism Male Middle Aged Pulmonary/Respiratory Tenofovir - analogs & derivatives Tenofovir - therapeutic use Tenofovir alafenamide Tenofovir disoproxil fumarate ALT HIV/HBV coinfection Tenofovir alafenamide Tenofovir disoproxil fumarate Cholesterol
ISSN:	1201-9712, 1878-3511
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!